Hospitex secured a large public tender for the University Hospital “Gaetano Martino” in Messina By Investing.com
PARIS–( BUSINESS WIRE )–Regulatory news:
Hospitex, the Italian leader in the production of medical devices and subsidiaries of the company SOMETHING SCIENTIFIC (Ikonisys SA) ( Euronext (EPA:) Growth Paris: ALIKO), announces today that it has secured a public tender for Azienda Ospedaliera Universitaria “Gaetano Martino” in Messina, Italy.
Contract, in the value of 668 thousand euros over three years, includes the option to extend for two additional years, bringing the total potential value to 1.025 million euros. The tender covers the supply of alcohol for medical and hospital use, a vital component in maintaining high standards of healthcare services.
Hospitex is accredited as a fiscal warehouse for alcohol by the Italian Customs Agency, a recognition that is among the most challenging to obtain due to complex regulatory, logistical, infrastructure and administrative requirements. This accreditation demonstrates Hospitex’s operational excellence and positions the company as a reliable supplier capable of operating in highly complex regulated environments.
The company’s expertise in hydroalcoholic solutions and pure alcohol production extends beyond Italy, as Hospitex serves healthcare facilities across Europe, underscoring its ability to deliver reliable, high-quality medical alcohol solutions on a wide scale.
Francesco Trisolini, director of Hospitexhe stated: “Securing this tender reaffirms our leadership in the healthcare sector and our ability to navigate the complexity of regulatory and logistical frameworks. Our fiscal warehouse accreditation highlights our operational excellence and demonstrates our readiness to meet the needs of domestic and international clients. We are proud to partner with Gaetano University Hospital Martino and remain committed to delivering critical supplies that support healthcare excellence.”
This achievement strengthens ALIKO SCIENTIFIC’s strategic position in the healthcare and life sciences sectors, supporting its growth goals and commitment to innovation.
About ALIKO SCIENTIFIC (Ikonisys SA)
Based in Paris, ALIKO SCIENTIFIC is the parent company of the international business ecosystem dedicated to the advancement of oncology diagnostics. Listed on Euronext Growth Paris under the symbol ALIKO, the company coordinates industrial, financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO SCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources and strategic investments to create a global center of excellence in oncology.
For more information, visit: www.alikoscientific.com
ABOUT ICONISIS
Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and detection of circulating tumor cells (CTC). Using advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys delivers unparalleled precision, scalability and efficiency in cancer diagnosis and treatment monitoring. Recognized as a pioneer in automation for the discovery of rare cells, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.
For more information, visit: www.ikonisys.com
About HOSPITEX
Hospitex, headquartered in Florence, Italy, is a global leader in cytology innovation. The company carries out its own research, development and production, thus ensuring the highest quality standards. Hospitex offers the most advanced liquid cytology (LBC) technology in the world, capable of processing any cytology specimen with unparalleled precision. Hospitex is uniquely positioned as the only company fully ready for seamless digital integration, paving the way for a transformative future in cytology diagnostics.
For more information, visit: www.hospitex.com
Waiver
This press release contains forward-looking statements about the prospects and development of the Company. These statements are sometimes identified by the use of future tenses, conditional tenses and forward-looking words such as “believe”, “intend”, “expect”, “intend”, “estimate”, “believe”, “should”, ” could”, “would” or “will” or, where appropriate, the negative of these expressions or any other similar variant or expression. This information is not historical data and should not be construed as a guarantee that the stated facts and data will occur. This information is based on data, assumptions and estimates that the Company considers reasonable. It is subject to change or modification due to uncertainties related to the economic, financial, competitive and regulatory environment. This information contains information relating to the Company’s intentions, estimates and objectives, particularly in relation to the Company’s market, strategy, growth, results, financial position and cash flow. The forward-looking information contained in this press release speaks only as of the date of this press release. The Company undertakes no obligation to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a rapidly changing competitive environment and therefore cannot predict all risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which any risk or combination of risks will materialize that could cause it to results differ materially from those expressed in any forward-looking information, we remind you that none of this forward-looking information is a guarantee of actual results.
See the original version on businesswire.com: https://www.businesswire.com/news/home/20250114677393/en/
Iconisys
Alessandro Mauri
financial director
investors@ikonisys.com
NewCap
Louis-Victor Delouvrier/Aurélie Manavarere
Investor relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94
NewCap
Nicolas Merigeau
Relations with the media
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98
Source: Ikonisys
